Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy?
Amelia Insa, Paloma Martín-Martorell, Raimondo Di Liello, et al.
Critical Reviews in Oncology/Hematology (2021) Vol. 169, pp. 103538-103538
Open Access | Times Cited: 22

Showing 22 citing articles:

Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study
Luis Paz‐Ares, Óscar Juan, Giannis Mountzios, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 24, pp. 2860-2872
Open Access | Times Cited: 28
CXCL9/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer
Raymond J. Lim, Ramin Salehi‐Rad, Linh M. Tran, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 4, pp. 101479-101479
Open Access | Times Cited: 25
Fibronectin promotes tumor angiogenesis and progression of non-small-cell lung cancer by elevating WISP3 expression via FAK/MAPK/ HIF-1α axis and activating wnt signaling pathway
Fei Zhou, Jianguo Sun, Lingyun Ye, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 26
Resistance to Immunotherapy in Non-small Cell Lung Cancer: Unraveling Causes, Developing Effective Strategies, and Exploring Potential Breakthroughs
Shuang Dong, Xiaoyu Li, Qing Huang, et al.
Drug Resistance Updates (2025) Vol. 81, pp. 101215-101215
Closed Access | Times Cited: 1
Lung Cancer—Epidemiology, Pathogenesis, Treatment and Molecular Aspect (Review of Literature)
Beata Smolarz, H Łukasiewicz, Dariusz Samulak, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 5, pp. 2049-2049
Open Access | Times Cited: 1
CAR T-cells for colorectal cancer immunotherapy: Ready to go?
Bouchra Ghazi, Adil El Ghanmi, Sarah Kandoussi, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 26
Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectives
Martin Reck, Sanjay Popat, Christian Grohé, et al.
Lung Cancer (2023) Vol. 179, pp. 107173-107173
Closed Access | Times Cited: 15
SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer
Jun Zhao, Xinmin Yu, Dingzhi Huang, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 2, pp. e006055-e006055
Open Access | Times Cited: 14
Immune-related pulmonary toxicities of checkpoint inhibitors in non-small cell lung cancer: Diagnosis, mechanism, and treatment strategies
Xinyu Guo, Shi Chen, Xueyan Wang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 14
Pan-Immune-Inflammatory Value in Patients with Non-Small-Cell Lung Cancer Undergoing Neoadjuvant Immunochemotherapy
Wenyu Zhai, Fangfang Duan, Yaobin Lin, et al.
Journal of Inflammation Research (2023) Vol. Volume 16, pp. 3329-3339
Open Access | Times Cited: 10
Efficacy and safety of camrelizumab plus famitinib in patients with previously treated non-small-cell lung cancer: a single-arm, phase II trial
Ming Gao, Xia Zhang, Huan Yan, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial
Carminia Maria Della Corte, Morena Fasano, Vincenza Ciaramella, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 13
Navigating the Complexity of Resistance in Lung Cancer Therapy: Mechanisms, Organoid Models, and Strategies for Overcoming Treatment Failure
Da Hyun Kang, Jisoo Lee, Subin Im, et al.
Cancers (2024) Vol. 16, Iss. 23, pp. 3996-3996
Open Access | Times Cited: 2
Immunoregulatory framework and the role of miRNA in the pathogenesis of NSCLC – A systematic review
Nikhil Samarth, Pooja Gulhane, Shailza Singh
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 7
Spatial proteomic profiling of tumor and stromal compartments in non‐small‐cell lung cancer identifies signatures associated with overall survival
Vahid Yaghoubi Naei, James Monkman, Habib Sadeghirad, et al.
Clinical & Translational Immunology (2024) Vol. 13, Iss. 7
Open Access | Times Cited: 1
Prognostic Value of Sarcopenia in Elderly Patients with Metastatic Non-Small-Cell Lung Cancer Undergoing Radiotherapy
Valerio Nardone, Alfonso Reginelli, Vittorio Patanè, et al.
Current Oncology (2024) Vol. 31, Iss. 11, pp. 6673-6685
Open Access | Times Cited: 1
Systematic analysis of lncRNA gene characteristics based on PD-1 immune related pathway for the prediction of non-small cell lung cancer prognosis
Hejian Chen, Shuiyu Xu, Yuhong Zhang, et al.
Mathematical Biosciences & Engineering (2023) Vol. 20, Iss. 6, pp. 9818-9838
Open Access | Times Cited: 1
Efficacy of immune checkpoint inhibitors along with chemotherapy in non-small cell lung cancer and the impact on adverse reactions and serum tumor markers.
Miao Xie, Xinlin Wang, Peng Wang, et al.
PubMed (2023) Vol. 15, Iss. 8, pp. 5276-5283
Closed Access | Times Cited: 1
Network pharmacology study to explore the multiple molecular mechanism of SH003 in the treatment of non-small cell lung cancer
Kangwook Lee, Yu‐Jeong Choi, Hae-In Lim, et al.
BMC Complementary Medicine and Therapies (2024) Vol. 24, Iss. 1
Open Access
Integrative Analysis of Bioinformatics and Machine Learning Algorithms Identifies a Novel Diagnostic Model Based on Costimulatory Molecule for Predicting Immune Microenvironment Status in Lung Adenocarcinoma
Wenyu Zhai, Fangfang Duan, Yizhi Wang, et al.
American Journal Of Pathology (2022) Vol. 192, Iss. 10, pp. 1433-1447
Closed Access | Times Cited: 2
Anti-tumor Activity of Cetuximab Plus Avelumab in Non-Small Cell Lung Cancer Patients Involves Innate Immunity Activation: Findings from the CAVE-Lung Trial
Carminia Maria Della Corte, Morena Fasano, Vincenza Ciaramella, et al.
Research Square (Research Square) (2022)
Open Access
A novel diagnostic model for predicting immune microenvironment subclass based on costimulatory molecules in lung squamous carcinoma
Fangfang Duan, Weisen Wang, Wenyu Zhai, et al.
Frontiers in Genetics (2022) Vol. 13
Open Access
Page 1

Scroll to top